Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2022-04-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司2021年度独立董事述职报告
Regulatory Filings
2022-04-24 Chinese
江苏浩欧博生物医药股份有限公司第二届董事会第十五次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting of Jiangsu Haobo Biopharmaceutical Co., Ltd. It includes approvals of various reports and proposals related to the 2021 annual report, financial statements, audit reports, profit distribution, internal control evaluation, and other governance matters. The document repeatedly states that these matters will be submitted to the 2021 annual general meeting for approval. The document is not the annual report itself but a board meeting resolution announcement concerning the annual report and related documents. It is not a simple announcement of report publication but a formal board meeting decision document. Therefore, it fits best under Board/Management Information (MANG) as it concerns board meeting resolutions and management decisions.
2022-04-24 Chinese
江苏浩欧博生物医药股份有限公司关联方非经营性资金占用及其他关联资金往来情况的专项报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项报告" (special report) on non-operating fund occupation and other related party fund transactions for the year 2021 by 江苏浩欧博生物医药股份有限公司. It includes references to audited financial statements for the year ended December 31, 2021, and mentions an unqualified audit opinion issued on April 22, 2022. The document contains detailed tables summarizing related party transactions and fund occupation, and it is explicitly stated that the report is prepared according to regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The document is signed by certified public accountants and approved by the board. This is a standalone audit-related report focusing on specific financial and regulatory compliance matters related to non-operating fund occupation and related party transactions, rather than a full annual report or general financial statement. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2021
2022-04-24 Chinese
江苏浩欧博生物医药股份有限公司第二届监事会第十三次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the approval of various proposals including the 2021 Annual Report, 2021 Annual Work Report of the Supervisory Board, 2021 Financial Final Report, 2022 Financial Budget Plan, reappointment of the audit firm, 2021 Profit Distribution Plan, 2022 Guarantee Quota Estimate, 2021 Fundraising Use Report, and 2022 Supervisory Board Remuneration. The document is a formal announcement of the Supervisory Board's meeting decisions and approvals, not the actual reports themselves. It references that the full reports are disclosed on the Shanghai Stock Exchange website and other media. The document length is short (2001 characters) and it serves as a meeting resolution announcement rather than a full financial or audit report. Therefore, it does not qualify as an Annual Report (10-K), Audit Report (AR), or Management Report (MDA). It is also not a voting result announcement (DVA) since it is a Supervisory Board meeting resolution, not a shareholder vote result. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement of Supervisory Board meeting resolutions and approvals.
2022-04-24 Chinese
江苏浩欧博生物医药股份有限公司2021年度利润分配方案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the fiscal year 2021 by Jiangsu Haobo Biomedical Co., Ltd. It details the dividend per share, total dividend amount, and the approval process including board and supervisory opinions. It explicitly states that the plan is subject to approval at the 2021 Annual General Meeting. The document is relatively short (1776 characters) and focuses on the dividend distribution plan rather than presenting full financial statements or comprehensive annual report content. Therefore, it is best classified as a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release.
2022-04-24 Chinese
江苏浩欧博生物医药股份有限公司2021年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制评价报告' which translates to '2021 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021, including financial and non-financial internal control defects, their identification, and rectification status. The document includes detailed internal control standards, defect classifications, and corrective actions. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The content aligns with an Audit Report / Information filing, which covers audit results and internal control assessments but is distinct from the full Annual Report (10-K). The document length is about 4600 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2021
2022-04-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.